How Many Clinical Trials Are Studying Amanita Muscaria for Mental Health? Zero.
That's not a rhetorical opener. It's a registry count. Searching ClinicalTrials.gov — the US federal registry where essentially all serious drug research is logged — for "Amanita muscaria" returns 0 studies. "Fly agaric" returns 0. "Muscimol" returns 2, and both are phase 1 studies that infused muscimol directly into brain tissue for epilepsy and movement disorders; one was terminated and the other withdrawn before enrolling anyone (registry checked 13 August 2026). By comparison, "psilocybin" returns 316 studies, 16 of them phase 3. So when an article promises "the future of microdosing in mental health therapy" and then pivots to Amanita muscaria, it's describing a future that has no present. There is a real psychedelic-medicine pipeline moving through regulators right now. Amanita is not in it, and the reasons why are specific and worth understanding.
The Pipeline Isn't a Microdosing Pipeline
Here's the first thing that gets blurred. The clinical programmes generating headlines — psilocybin for treatment-resistant depression, MDMA for PTSD — don't use microdoses. They use one or two large, supervised doses paired with hours of psychological support, in a clinic, with monitoring. Compass Pathways' phase 3 protocol uses a single 25 mg dose of synthetic psilocybin. That's roughly two orders of magnitude above what the microdosing community means by a microdose.
So "microdosing is the future of mental health treatment" inverts what's actually happening. The dosing model being tested is the opposite one. Of the 316 psilocybin studies on the registry, exactly one phase 3 trial tests a microdose — a psilocybin microdose for psychological and existential distress in palliative care, currently recruiting. One. That's the entire late-stage microdosing pipeline, in any substance, for any mental-health indication.
FDA's Definition of "Psychedelic" Excludes Amanita by Mechanism
In July 2026 the FDA finalised its guidance Psychedelic Drugs: Considerations for Clinical Investigations, published in the Federal Register on 14 July 2026 and finalising the draft first issued in June 2023 (Federal Register, docket FDA-2023-D-1987, 2026). This is the roadmap sponsors follow to bring a psychedelic through to approval — and it's genuinely new, less than a month old at the time of writing.
Read what it covers. FDA states that within the guidance, "the term psychedelics refers to 'classic psychedelics,' typically understood to be drugs such as psilocybin and lysergic acid diethylamide (LSD) that act on the brain's serotonin system, as well as 'entactogens' or 'empathogens' such as methylenedioxymethamphetamine (MDMA)" (FDA, 23 June 2023). Muscimol acts on none of those systems. It's a selective GABA-A receptor agonist (Michelot & Melendez-Howell, Mycological Research, 2003), which puts Amanita in the pharmacological company of benzodiazepines and alcohol, not psilocybin. The regulatory framework everyone points to when they say "the future" was not written with this mushroom in scope.
What the Psilocybin Programme Actually Delivered
The pipeline is real, and it's worth being accurate about its size. Compass Pathways' COMP005 trial hit its primary endpoint: a single 25 mg dose produced a mean treatment difference of −3.6 points on the MADRS depression scale at six weeks versus placebo (95% CI −5.7 to −1.5, p<0.001) (Compass Pathways, 23 June 2025). Poster data presented at the 2026 ASCP annual meeting reported that early response predicted separation sustained through 26 weeks (Psychiatric Times, 2026). A second pivotal trial, COMP006, has also met its primary endpoint, with 26-week data due in the second half of 2026.
Statistically robust, and a 3.6-point MADRS difference is a modest effect that clinicians will argue about for years. That's what an actual result looks like: specific, bounded, contestable. It's a useful yardstick for the claims made about Amanita, which are never expressed in a number anyone can check.
And What It Hasn't Delivered
The field's most advanced programme was rejected. On 9 August 2024 the FDA issued a complete response letter to Lykos Therapeutics for MDMA-assisted therapy for PTSD, requiring an additional phase 3 trial before it would reconsider. A central concern was functional unblinding — participants could tell whether they'd received the drug, which undermines the placebo comparison. Lykos cut roughly three-quarters of its staff within weeks (FierceBiotech, 2024).
Notice that the objection was methodological, not ideological. And it applies with more force, not less, to microdosing claims: if unblinding can sink a phase 3 programme for a drug with a large measured effect, uncontrolled self-reports about a mushroom of unknown potency don't clear anything. The finalised FDA guidance now specifically recommends that sponsors use questionnaires to measure participants' expectations of drug effects, precisely to make results interpretable — an acknowledgement of how much expectancy contaminates this area.
Has a GABA-A Drug Ever Been Taken Down This Road?
Yes, and the result is instructive. Gaboxadol is a rigidified muscimol analogue — the closest thing to a pharmaceutical version of Amanita's active compound that has ever reached late-stage trials. Merck and Lundbeck took it through phase 3 for insomnia and then abandoned it in 2007, concluding that its overall clinical profile didn't support further development. It was never filed with the FDA or any other regulator.
That's the nearest precedent available: a purified, dose-standardised, single-target relative of muscimol, backed by two large pharmaceutical companies, that failed on efficacy rather than on stigma or scheduling. We go through what gaboxadol's trial record does and doesn't tell us about Amanita in our piece on the 12-month trial that should reframe every Amanita microdosing journey. The short version: it's genuinely reassuring on tolerance, and genuinely discouraging on benefit.
What Would Actually Have to Happen First
Suppose someone wanted to move Amanita into that pipeline tomorrow. The first obstacle isn't regulatory hostility, it's chemistry. You cannot run a dose-response study on a material whose dose you can't specify. The 2026 Frontiers in Pharmacology review notes there are still no widely recognised testing standards for retail Amanita products, and that published figures for ibotenic acid and muscimol content "do not establish a reliable dose–response relationship"; its overall assessment is that the evidence base "remains limited predominantly to case reports, observational studies, and user-reported experiences, while controlled clinical studies are lacking" (Ordak, Frontiers in Pharmacology, 2026).
So the sequence would run: a standardised, characterised drug substance — almost certainly purified muscimol rather than mushroom material — then formal toxicology, then an investigational new drug application, then phase 1 safety, then phase 2 dose-ranging, then two adequate and well-controlled phase 3 trials. Psilocybin has been walking that path since 2018 and isn't finished. Nobody has taken step one for Amanita.
What This Means If You're Reading Claims About Amanita and Mental Health
The honest position is narrow. Muscimol's mechanism is well characterised, and GABA-A is a legitimate target that established anxiolytics and hypnotics act on — that much is real pharmacology, and it's why the "it's plausible" framing keeps recurring. But a plausible mechanism is not evidence of benefit, and Amanita muscaria is not an approved treatment for depression, anxiety, PTSD, or any other condition. There is no trial evidence that it treats any of them, at any dose.
If you're managing a mental-health condition, the approved treatments and a clinician are the path with evidence behind it. If you're following the psychedelic-medicine story out of interest, follow the actual pipeline — and notice that it's a story about supervised high doses of standardised compounds under regulatory scrutiny, which is close to the opposite of unsupervised microdosing with an unstandardised mushroom. Our practical guide to mindful Amanita use covers what's actually known, and the adverse-event record covers what shows up in the clinical literature that does exist.
The Bottom Line
"The future of microdosing in mental health therapy" describes something real, but it isn't about Amanita and it isn't about microdosing. It's about supervised, high-dose, standardised serotonergic compounds working slowly through a regulatory process that just got its own finalised FDA guidance in July 2026 — a process that has produced one modest positive phase 3 readout and one high-profile rejection. Amanita muscaria has zero registered studies for any mental-health indication, sits outside FDA's working definition of a psychedelic, and lacks the basic standardisation that would let a trial begin. Any article that folds it into that story is borrowing credibility that the research hasn't extended.
Nothing here is medical advice. Amanita muscaria is not an approved treatment for any condition. If you take sedatives, anti-anxiety medication, or sleep medication, or you're being treated for a mental-health condition, speak to a clinician before considering any GABA-A active substance — and see our note on Amanita and anxiety claims for why the mechanism-to-treatment leap doesn't hold.
Frequently Asked Questions
Are there any clinical trials of Amanita muscaria for mental health?
No. A ClinicalTrials.gov search on 13 August 2026 returned zero registered studies for "Amanita muscaria" or "fly agaric". The two muscimol entries are phase 1 studies that infused the compound directly into brain tissue for epilepsy and movement disorders; one was terminated and one withdrawn.
Is microdosing what's being tested in psychedelic clinical trials?
No — the opposite. Phase 3 psychedelic trials use one or two large supervised doses with psychological support, such as Compass Pathways' single 25 mg psilocybin dose. Across the whole registry, only one phase 3 trial tests a psychedelic microdose, for distress in palliative care.
Does FDA's psychedelic guidance apply to Amanita muscaria?
Not as written. FDA defines psychedelics in that guidance as classic psychedelics acting on the serotonin system, such as psilocybin and LSD, plus entactogens such as MDMA. Muscimol is a GABA-A agonist and falls outside all three categories.
How strong were the psilocybin phase 3 results?
Statistically clear but modest in size. COMP005 found a 3.6-point greater reduction on the MADRS scale at six weeks versus placebo (p<0.001), with sustained separation through 26 weeks in early responders. A second pivotal trial has also met its primary endpoint, with 26-week data expected in late 2026.
Why was MDMA-assisted therapy rejected if the trials worked?
FDA issued a complete response letter in August 2024 requiring another phase 3 trial. A central issue was functional unblinding — participants could tell they had received the active drug, which weakens the placebo comparison and makes the effect size hard to interpret.
Has any drug like muscimol been through late-stage trials?
Gaboxadol, a rigidified muscimol analogue, completed phase 3 trials for insomnia and was abandoned by Merck and Lundbeck in 2007 because its overall clinical profile didn't support further development. It was never submitted to any regulator.
What would need to happen before Amanita could be studied properly?
A standardised, characterised drug substance would have to exist first — likely purified muscimol rather than mushroom material — followed by formal toxicology, an investigational new drug application, and phase 1 through 3 trials. There are currently no recognised testing standards for retail Amanita products.
Written by Viktor, Amanita Store. We sell dried Amanita muscaria caps and tincture as wellness and collector items, not as treatments — which is why this page reports registry counts instead of promises.